{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:35:33Z","timestamp":1772796933536,"version":"3.50.1"},"reference-count":96,"publisher":"Harborside Press, LLC","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Limited data exist on the impact of immunotherapy use in ethnic minority patients with non\u2013small cell lung cancer (NSCLC), because they have been underrepresented in immunotherapy trials. This study aims to evaluate race\/ethnicity and other demographic, socioeconomic, and clinical factors of patients with metastatic NSCLC treated with first-line immunotherapy. <jats:bold>Methods:<\/jats:bold> A retrospective cohort study of 5,920 patients diagnosed with lung cancer treated at Montefiore Einstein Cancer Center from January 1, 2013, to June 1, 2022, was used to identify patients with metastatic NSCLC without <jats:italic>EGFR<\/jats:italic>, <jats:italic>ALK<\/jats:italic>, or <jats:italic>ROS1<\/jats:italic> alterations who underwent first-line immunotherapy (n=248). The primary endpoint was overall survival (OS), with secondary endpoints of progression-free survival (PFS) and time to discontinuation (TTD) from the start of immunotherapy. <jats:bold>Results:<\/jats:bold> Among the 248 patients, median follow-up time was 12.0 months, median age at start of treatment was 66 years, and 39.1% were non-Hispanic Black, 30.2% were Hispanic, and 30.7% were non-Hispanic White. OS (<jats:italic>P<\/jats:italic>=.39), PFS (<jats:italic>P<\/jats:italic>=.29), and TTD (<jats:italic>P<\/jats:italic>=.98) were similar among racial\/ethnic groups. Patients with an ECOG performance status (PS) of &lt;2 at the start of immunotherapy had longer OS compared with those with ECOG PS of \u22652 (<jats:italic>P<\/jats:italic>&lt;.0001). PD-L1 expression (&lt;50% vs \u226550%; <jats:italic>P<\/jats:italic>=.03) and body mass index (BMI) (<jats:italic>P<\/jats:italic>=.01) were also found to be associated with PFS, and ECOG PS (<jats:italic>P<\/jats:italic>&lt;.0001) and BMI (<jats:italic>P<\/jats:italic>=.02) were associated with TTD. In a multivariate analysis of OS and PFS, ECOG PS was the only variable found to be significant. <jats:bold>Conclusions:<\/jats:bold> Our study observed similar benefits of immunotherapy in patients with metastatic NSCLC in different racial and ethnic groups. Furthermore, ECOG PS was associated with OS, and PD-L1 expression and BMI were associated with PFS and TTD. These findings help identify potential factors associated with outcomes and care while patients are undergoing immunotherapy.<\/jats:p>","DOI":"10.6004\/jnccn.2023.7064","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T20:48:14Z","timestamp":1702327694000},"page":"1269-1280.e5","source":"Crossref","is-referenced-by-count":6,"title":["Similar Efficacy Observed for First-Line Immunotherapy in Racial\/Ethnic Minority Patients With Metastatic NSCLC"],"prefix":"10.6004","volume":"21","author":[{"given":"Matthew","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Montefiore Medical Center, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyou","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Montefiore Medical Center, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Montefiore Medical Center, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Health Information Management, Montefiore Medical Center, Bronx, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaonan","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balazs","family":"Halmos","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Montefiore Medical Center, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Dean","family":"Hosgood","sequence":"additional","affiliation":[{"name":"Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiying","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Montefiore Medical Center, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Lancet","first-page":"1415","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi F","year":"2016","unstructured":"Barlesi F, Mazieres J, Merlio JP,  Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 2016;387:1415\u20131426."},{"key":"B2","series-title":"Cancer Discov","first-page":"596","article-title":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","volume":"7","author":"Jordan EJ","year":"2017","unstructured":"Jordan EJ, Kim HR, Arcila ME,  Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov 2017;7:596\u2013609."},{"key":"B3","series-title":"N Engl J Med","first-page":"2018","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon EB","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R,  Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018\u20132028."},{"key":"B4","series-title":"Lancet","first-page":"1540","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst RS","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW,  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540\u20131550."},{"key":"B5","series-title":"N Engl J Med","first-page":"1823","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck M","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG,  Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823\u20131833."},{"key":"B6","series-title":"Lancet","first-page":"1819","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok TS","year":"2019","unstructured":"Mok TS, Wu YL, Kudaba I,  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 2019;393:1819\u20131830."},{"key":"B7","series-title":"Lancet Oncol","first-page":"1497","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer CJ","year":"2016","unstructured":"Langer CJ, Gadgeel SM, Borghaei H,  Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016;17:1497\u20131508."},{"key":"B8","series-title":"N Engl J Med","first-page":"2078","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi L","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S,  Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018;378:2078\u20132092."},{"key":"B9","series-title":"N Engl J Med","first-page":"2040","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares L","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D,  Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 2018;379:2040\u20132051."},{"key":"B10","series-title":"N Engl J Med","first-page":"2342","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia SJ","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D,  Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018;379:2342\u20132350."},{"key":"B11","series-title":"J Thorac Oncol","first-page":"653","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial","volume":"16","author":"Nishio M","year":"2021","unstructured":"Nishio M, Barlesi F, West H,  Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial. J Thorac Oncol 2021;16:653\u2013664."},{"key":"B12","series-title":"JNCI Cancer Spectr","first-page":"pkac015","article-title":"Association of personal characteristics and effectiveness of immunotherapy in late-stage non-small cell lung cancer: a systematic review","volume":"6","author":"Patel K","year":"2022","unstructured":"Patel K, Alpert N, Tuminello S,  Association of personal characteristics and effectiveness of immunotherapy in late-stage non-small cell lung cancer: a systematic review. JNCI Cancer Spectr 2022;6:pkac015."},{"key":"B13","series-title":"Br J Cancer","first-page":"551","article-title":"Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence","volume":"110","author":"Booth CM","year":"2014","unstructured":"Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer 2014;110:551\u2013555."},{"key":"B14","series-title":"J Multidiscip Healthc","first-page":"295","article-title":"Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making","volume":"11","author":"Katkade VB","year":"2018","unstructured":"Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscip Healthc 2018;11:295\u2013304."},{"key":"B15","series-title":"Cancer","first-page":"1532","article-title":"Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period","volume":"120","author":"Aizer AA","year":"2014","unstructured":"Aizer AA, Wilhite TJ, Chen MH,  Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer 2014;120:1532\u20131539."},{"key":"B16","series-title":"J Natl Cancer Inst","first-page":"984","article-title":"Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group","volume":"101","author":"Albain KS","year":"2009","unstructured":"Albain KS, Unger JM, Crowley JJ,  Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst 2009;101:984\u2013992."},{"key":"B17","series-title":"Cancer","first-page":"4495","article-title":"The influence of Hispanic ethnicity on nonsmall cell lung cancer histology and patient survival: an analysis of the Survival, Epidemiology, and End Results database","volume":"118","author":"Saeed AM","year":"2012","unstructured":"Saeed AM, Toonkel R, Glassberg MK,  The influence of Hispanic ethnicity on nonsmall cell lung cancer histology and patient survival: an analysis of the Survival, Epidemiology, and End Results database. Cancer 2012;118:4495\u20134501."},{"key":"B18","series-title":"Cancer Causes Control","first-page":"1231","article-title":"Race\/ethnicity and lung cancer survival in the United States: a meta-analysis","volume":"30","author":"Klugman M","year":"2019","unstructured":"Klugman M, Xue X, Hosgood HD III. Race\/ethnicity and lung cancer survival in the United States: a meta-analysis. Cancer Causes Control 2019;30:1231\u20131241."},{"key":"B19","series-title":"JAMA Netw Open","first-page":"e2219535","article-title":"Association between Food and Drug Administration approval and disparities in immunotherapy use among patients with cancer in the US","volume":"5","author":"Ermer T","year":"2022","unstructured":"Ermer T, Canavan ME, Maduka RC,  Association between Food and Drug Administration approval and disparities in immunotherapy use among patients with cancer in the US. JAMA Netw Open 2022;5:e2219535."},{"key":"B20","series-title":"Am J Clin Oncol","first-page":"193","article-title":"Analysis of heterogeneity in survival benefit of immunotherapy in oncology according to patient demographics and performance status: a systematic review and meta-analysis of overall survival data","volume":"43","author":"Butaney M","year":"2020","unstructured":"Butaney M, Satkunasivam R, Goldberg H,  Analysis of heterogeneity in survival benefit of immunotherapy in oncology according to patient demographics and performance status: a systematic review and meta-analysis of overall survival data. Am J Clin Oncol 2020;43:193\u2013202."},{"key":"B21","series-title":"Cancer","first-page":"5040","article-title":"Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer","volume":"126","author":"Nazha B","year":"2020","unstructured":"Nazha B, Goyal S, Chen Z,  Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer. Cancer 2020;126:5040\u20135049."},{"key":"B22","series-title":"Oncologist","first-page":"694","article-title":"Safety and efficacy of first-line pembrolizumab in Black patients with metastatic non-small cell lung cancer","volume":"26","author":"Peravali M","year":"2021","unstructured":"Peravali M, Ahn J, Chen K,  Safety and efficacy of first-line pembrolizumab in Black patients with metastatic non-small cell lung cancer. Oncologist 2021;26:694\u2013700."},{"key":"B23","series-title":"Oncologist","first-page":"e1226","article-title":"Analysis of real-world data to investigate the impact of race and ethnicity on response to programmed cell death-1 and programmed cell death-ligand 1 inhibitors in advanced non-small cell lung cancers","volume":"26","author":"Ayers KL","year":"2021","unstructured":"Ayers KL, Mullaney T, Zhou X,  Analysis of real-world data to investigate the impact of race and ethnicity on response to programmed cell death-1 and programmed cell death-ligand 1 inhibitors in advanced non-small cell lung cancers. Oncologist 2021;26:e1226\u20131239."},{"key":"B24","series-title":"Med Oncol","first-page":"109","article-title":"Clinical outcomes of African American patients with advanced or metastatic non-small cell lung cancer on nivolumab in a single community-based cancer center","volume":"35","author":"Tiu AC","year":"2018","unstructured":"Tiu AC, Potdar R, Djibo DA,  Clinical outcomes of African American patients with advanced or metastatic non-small cell lung cancer on nivolumab in a single community-based cancer center. Med Oncol 2018;35:109."},{"key":"B25","series-title":"Cancer Res Commun","first-page":"806","article-title":"Persistent ethnicity-associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access","volume":"2022","author":"Florez MA","year":"2022","unstructured":"Florez MA, Kemnade JO, Chen N,  Persistent ethnicity-associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access. Cancer Res Commun 2022;2022:806\u2013813."},{"key":"B26","article-title":"American community survey data","unstructured":"United States Census Bureau. American community survey data. Accessed July 1, 2023. Available at: https:\/\/www.census.gov\/programs-surveys\/acs\/data.html"},{"key":"B27","series-title":"J Clin Oncol","first-page":"2518","article-title":"Five-year overall survival for patients with advanced non\u2012small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study","volume":"37","author":"Garon EB","year":"2019","unstructured":"Garon EB, Hellmann MD, Rizvi NA,  Five-year overall survival for patients with advanced non\u2012small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol 2019;37:2518\u20132527."},{"key":"B28","series-title":"J Clin Oncol","first-page":"1580","article-title":"Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1\u2012positive, advanced non\u2012small-cell lung cancer in the KEYNOTE-010 study","volume":"38","author":"Herbst RS","year":"2020","unstructured":"Herbst RS, Garon EB, Kim DW,  Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1\u2012positive, advanced non\u2012small-cell lung cancer in the KEYNOTE-010 study. J Clin Oncol 2020;38:1580\u20131590."},{"key":"B29","series-title":"J Clin Oncol","first-page":"2339","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck M","year":"2021","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG,  Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50. J Clin Oncol 2021;39:2339\u20132349."},{"key":"B30","series-title":"J Immunother Cancer","article-title":"KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1\u2013positive, locally advanced or metastatic non\u2013small-cell lung cancer","volume":"9","author":"de Castro G","year":"2021","unstructured":"de Castro G, Kudaba I, Wu YL,  KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1\u2013positive, locally advanced or metastatic non\u2013small-cell lung cancer. J Immunother Cancer 2021;9(Suppl 2):Abstract 363."},{"key":"B31","series-title":"J Thorac Oncol","first-page":"162","article-title":"Long-term overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC","volume":"16","author":"Awad MM","year":"2021","unstructured":"Awad MM, Gadgeel SM, Borghaei H,  Long-term overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC. J Thorac Oncol 2021;16:162\u2013168."},{"key":"B32","series-title":"J Thorac Oncol","article-title":"Pembrolizumab + pemetrexed-platinum vs pemetrexed-platinum for metastatic NSCLC: 4-year follow-up from KEYNOTE-189","volume":"16","author":"Gray J","year":"2021","unstructured":"Gray J, Rodr\u00edguez-Abreu D, Powell SF,  Pembrolizumab + pemetrexed-platinum vs pemetrexed-platinum for metastatic NSCLC: 4-year follow-up from KEYNOTE-189. J Thorac Oncol 2021;16(Suppl):Abstract FP13.02."},{"key":"B33","series-title":"J Thorac Oncol","article-title":"First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407","volume":"16","author":"Robinson A","year":"2021","unstructured":"Robinson A, Vicente Baz D, Tafreshi A,  First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407. J Thorac Oncol 2021;16(Suppl):Abstract 960."},{"key":"B34","series-title":"Clin Med Insights Oncol","first-page":"11795549211004489","article-title":"Real-world outcomes and clinical predictors of immune checkpoint inhibitor monotherapy in advanced lung cancer","volume":"15","author":"Zhang S","year":"2021","unstructured":"Zhang S, Pease DF, Kulkarni AA,  Real-world outcomes and clinical predictors of immune checkpoint inhibitor monotherapy in advanced lung cancer. Clin Med Insights Oncol 2021;15:11795549211004489."},{"key":"B35","series-title":"Curr Oncol","first-page":"4213","article-title":"Effectiveness and safety of first-line pembrolizumab in older adults with PD-L1 positive non-small cell lung cancer: a retrospective cohort study of the Alberta Immunotherapy Database","volume":"28","author":"Grosjean HAI","year":"2021","unstructured":"Grosjean HAI, Dolter S, Meyers DE,  Effectiveness and safety of first-line pembrolizumab in older adults with PD-L1 positive non-small cell lung cancer: a retrospective cohort study of the Alberta Immunotherapy Database. Curr Oncol 2021;28:4213\u20134222."},{"key":"B36","series-title":"J Transl Med","first-page":"235","article-title":"Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"18","author":"An Y","year":"2020","unstructured":"An Y, Wu Z, Wang N,  Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J Transl Med 2020;18:235."},{"key":"B37","series-title":"Lung Cancer Manag","first-page":"LMT26","article-title":"Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer","volume":"9","author":"Gelibter A","year":"2020","unstructured":"Gelibter A, Occhipinti M, Pisegna S,  Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer. Lung Cancer Manag 2020;9:LMT26."},{"key":"B38","series-title":"JAMA Oncol","first-page":"512","article-title":"Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer","volume":"6","author":"Kichenadasse G","year":"2020","unstructured":"Kichenadasse G, Miners JO, Mangoni AA,  Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer. JAMA Oncol 2020;6:512\u2013518."},{"key":"B39","series-title":"Lung Cancer","first-page":"140","article-title":"The impact of body mass index on the efficacy of anti-PD-1\/PD-L1 antibodies in patients with non-small cell lung cancer","volume":"139","author":"Ichihara E","year":"2020","unstructured":"Ichihara E, Harada D, Inoue K,  The impact of body mass index on the efficacy of anti-PD-1\/PD-L1 antibodies in patients with non-small cell lung cancer. Lung Cancer 2020;139:140\u2013145."},{"key":"B40","series-title":"J Immunother Cancer","first-page":"e001403","article-title":"Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression \u2265 50%: a multicenter study with external validation","volume":"8","author":"Cortellini A","year":"2020","unstructured":"Cortellini A, Ricciuti B, Tiseo M,  Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression \u2265 50%: a multicenter study with external validation. J Immunother Cancer 2020;8:e001403."},{"key":"B41","series-title":"J Immunother Cancer","first-page":"57","article-title":"A multicenter study of body mass index in cancer patients treated with anti-PD-1\/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable","volume":"7","author":"Cortellini A","year":"2019","unstructured":"Cortellini A, Bersanelli M, Buti S,  A multicenter study of body mass index in cancer patients treated with anti-PD-1\/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J Immunother Cancer 2019;7:57."},{"key":"B42","series-title":"Oncoimmunology","first-page":"1950411","article-title":"Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study","volume":"10","author":"Morimoto K","year":"2021","unstructured":"Morimoto K, Uchino J, Yokoi T,  Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study. Oncoimmunology 2021;10:1950411."},{"key":"B43","series-title":"J Cachexia Sarcopenia Muscle","first-page":"657","article-title":"The prognostic value of weight and body composition changes in patients with non-small-cell lung cancer treated with nivolumab","volume":"12","author":"Degens JHRJ","year":"2021","unstructured":"Degens JHRJ, Dingemans AC, Willemsen ACH,  The prognostic value of weight and body composition changes in patients with non-small-cell lung cancer treated with nivolumab. J Cachexia Sarcopenia Muscle 2021;12:657\u2013664."},{"key":"B44","series-title":"Lung Cancer","first-page":"19","article-title":"Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors","volume":"143","author":"Roch B","year":"2020","unstructured":"Roch B, Coffy A, Jean-Baptiste S,  Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors. Lung Cancer 2020;143:19\u201326."},{"key":"B45","series-title":"Transl Lung Cancer Res","first-page":"3538","article-title":"Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors: results from a prospective, observational study","volume":"10","author":"Rounis K","year":"2021","unstructured":"Rounis K, Makrakis D, Tsigkas AP,  Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors: results from a prospective, observational study. Transl Lung Cancer Res 2021;10:3538\u20133549."},{"key":"B46","series-title":"Transl Lung Cancer Res","first-page":"168","article-title":"The landscape of cancer cachexia in advanced non-small cell lung cancer: a narrative review","volume":"12","author":"Morita-Tanaka S","year":"2023","unstructured":"Morita-Tanaka S, Yamada T, Takayama K. The landscape of cancer cachexia in advanced non-small cell lung cancer: a narrative review. Transl Lung Cancer Res 2023;12:168\u2013180."},{"key":"B47","series-title":"Nat Med","first-page":"141","article-title":"Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade","volume":"25","author":"Wang Z","year":"2019","unstructured":"Wang Z, Aguilar EG, Luna JI,  Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med 2019;25:141\u2013151."},{"key":"B48","series-title":"Cancer Immunol Immunother","first-page":"89","article-title":"Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis","volume":"70","author":"Guzman-Prado Y","year":"2021","unstructured":"Guzman-Prado Y, Ben Shimol J, Samson O. Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis. Cancer Immunol Immunother 2021;70:89\u2013100."},{"key":"B49","series-title":"ESMO Open","first-page":"100107","article-title":"High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different solid tumors","volume":"6","author":"G\u00fclave B","year":"2021","unstructured":"G\u00fclave B, Hew MN, de Groot JS,  High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different solid tumors. ESMO Open 2021;6:100107."},{"key":"B50","series-title":"JAMA Oncol","first-page":"102","article-title":"Association of body mass index with the safety profile of nivolumab with or without ipilimumab","volume":"9","author":"McQuade JL","year":"2023","unstructured":"McQuade JL, Hammers H, Furberg H,  Association of body mass index with the safety profile of nivolumab with or without ipilimumab. JAMA Oncol 2023;9:102\u2013111."},{"key":"B51","series-title":"J Thorac Oncol","first-page":"125","article-title":"Prevalence of poor performance status in lung cancer patients: implications for research","volume":"3","author":"Lilenbaum RC","year":"2008","unstructured":"Lilenbaum RC, Cashy J, Hensing TA,  Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol 2008;3:125\u2013129."},{"key":"B52","series-title":"Cancer","first-page":"2639","article-title":"Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma","volume":"92","author":"Sweeney CJ","year":"2001","unstructured":"Sweeney CJ, Zhu J, Sandler AB,  Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 2001;92:2639\u20132647."},{"key":"B53","series-title":"Cancer Treat Rev","first-page":"102394","article-title":"The use of immunotherapy in older patients with advanced non-small cell lung cancer","volume":"106","author":"Tagliamento M","year":"2022","unstructured":"Tagliamento M, Frelaut M, Baldini C,  The use of immunotherapy in older patients with advanced non-small cell lung cancer. Cancer Treat Rev 2022;106:102394."},{"key":"B54","series-title":"Semin Oncol","first-page":"220","article-title":"FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1\/PD-L1 blocking antibodies","volume":"45","author":"Marur S","year":"2018","unstructured":"Marur S, Singh H, Mishra-Kalyani P,  FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1\/PD-L1 blocking antibodies. Semin Oncol 2018;45:220\u2013225."},{"key":"B55","series-title":"Cancers (Basel)","first-page":"236","article-title":"A review of recent advances in the treatment of elderly and poor performance NSCLC","volume":"10","author":"Carmichael JA","year":"2018","unstructured":"Carmichael JA, Wing-San Mak D, O\u2019Brien M. A review of recent advances in the treatment of elderly and poor performance NSCLC. Cancers (Basel) 2018;10:236."},{"key":"B56","series-title":"Med Oncol","first-page":"132","article-title":"Patient performance status and cancer immunotherapy efficacy: a meta-analysis","volume":"35","author":"Bersanelli M","year":"2018","unstructured":"Bersanelli M, Brighenti M, Buti S,  Patient performance status and cancer immunotherapy efficacy: a meta-analysis. Med Oncol 2018;35:132."},{"key":"B57","series-title":"J Thorac Oncol","article-title":"Elderly lung cancer patients on immunotherapy: preliminary results from the ELDERS study","volume":"12","author":"Gomes F","year":"2017","unstructured":"Gomes F, Woolley S, Califano R,  Elderly lung cancer patients on immunotherapy: preliminary results from the ELDERS study. J Thorac Oncol 2017;12(Suppl 2):Abstract MA 10.07."},{"key":"B58","series-title":"Lancet Respir Med","first-page":"895","article-title":"Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial","volume":"8","author":"Middleton G","year":"2020","unstructured":"Middleton G, Brock K, Savage J,  Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. Lancet Respir Med 2020;8:895\u2013904."},{"key":"B59","series-title":"Transl Lung Cancer Res","first-page":"1866","article-title":"Impact of gender on response to immune checkpoint inhibitors in patients with non-small cell lung cancer undergoing second- or later-line treatment","volume":"11","author":"Choi MG","year":"2022","unstructured":"Choi MG, Choi CM, Lee DH,  Impact of gender on response to immune checkpoint inhibitors in patients with non-small cell lung cancer undergoing second- or later-line treatment. Transl Lung Cancer Res 2022;11:1866\u20131876."},{"key":"B60","series-title":"Transl Lung Cancer Res","first-page":"2917","article-title":"First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis","volume":"10","author":"Facchinetti F","year":"2021","unstructured":"Facchinetti F, Di Maio M, Perrone F,  First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis. Transl Lung Cancer Res 2021;10:2917\u20132936."},{"key":"B61","series-title":"JNCI Cancer Spectr","first-page":"pkac013","article-title":"Immunotherapy outcomes in individuals with non-small cell lung cancer and poor performance status","volume":"6","author":"Veluswamy R","year":"2022","unstructured":"Veluswamy R, Hu L, Smith C,  Immunotherapy outcomes in individuals with non-small cell lung cancer and poor performance status. JNCI Cancer Spectr 2022;6:pkac013."},{"key":"B62","series-title":"Cancer Treat Rev","first-page":"69","article-title":"Non-small cell lung cancer brain metastases and the immune system: from brain metastases development to treatment","volume":"68","author":"El Rassy E","year":"2018","unstructured":"El Rassy E, Botticella A, Kattan J,  Non-small cell lung cancer brain metastases and the immune system: from brain metastases development to treatment. Cancer Treat Rev 2018;68:69\u201379."},{"key":"B63","series-title":"Curr Oncol Rep","first-page":"48","article-title":"Epidemiology of brain metastases","volume":"14","author":"Nayak L","year":"2012","unstructured":"Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep 2012;14:48\u201354."},{"key":"B64","series-title":"Neuro Oncol","first-page":"122","article-title":"Incidence of brain metastasis at initial presentation of lung cancer","volume":"17","author":"Villano JL","year":"2015","unstructured":"Villano JL, Durbin EB, Normandeau C,  Incidence of brain metastasis at initial presentation of lung cancer. Neuro Oncol 2015;17:122\u2013128."},{"key":"B65","series-title":"Neurooncol Adv","first-page":"v52","article-title":"Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies","volume":"3","author":"Myall NJ","year":"2021","unstructured":"Myall NJ, Yu H, Soltys SG,  Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies. Neurooncol Adv 2021;3(Suppl 5):v52\u201362."},{"key":"B66","series-title":"Clin Lung Cancer","first-page":"e373","article-title":"Non-small-cell lung cancer with brain metastasis at presentation","volume":"19","author":"Waqar SN","year":"2018","unstructured":"Waqar SN, Samson PP, Robinson CG,  Non-small-cell lung cancer with brain metastasis at presentation. Clin Lung Cancer 2018;19:e373\u2013379."},{"key":"B67","series-title":"J Clin Oncol","first-page":"3773","article-title":"Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient","volume":"38","author":"Sperduto PW","year":"2020","unstructured":"Sperduto PW, Mesko S, Li J,  Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. J Clin Oncol 2020;38:3773\u20133784."},{"key":"B68","series-title":"Cancer Treat Rev","first-page":"139","article-title":"The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer","volume":"45","author":"Peters S","year":"2016","unstructured":"Peters S, Bexelius C, Munk V,  The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev 2016;45:139\u2013162."},{"key":"B69","series-title":"Neuro Oncol","first-page":"1511","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study","volume":"19","author":"Cagney DN","year":"2017","unstructured":"Cagney DN, Martin AM, Catalano PJ,  Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol 2017;19:1511\u20131521."},{"key":"B70","series-title":"JTO Clin Res Rep","first-page":"100205","article-title":"Outcomes with pembrolizumab monotherapy in patients with programmed death-ligand 1-positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001, 010, 024, and 042","volume":"2","author":"Mansfield AS","year":"2021","unstructured":"Mansfield AS, Herbst RS, de Castro G Jr,  Outcomes with pembrolizumab monotherapy in patients with programmed death-ligand 1-positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001, 010, 024, and 042. JTO Clin Res Rep 2021;2:100205."},{"key":"B71","series-title":"J Thorac Oncol","first-page":"1883","article-title":"Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: pooled analysis of KEYNOTE-021, -189, and -407","volume":"16","author":"Powell SF","year":"2021","unstructured":"Powell SF, Rodr\u00edguez-Abreu D, Langer CJ,  Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: pooled analysis of KEYNOTE-021, -189, and -407. J Thorac Oncol 2021;16:1883\u20131892."},{"key":"B72","series-title":"Cancers (Basel)","first-page":"2141","article-title":"Challenges and novel opportunities of radiation therapy for brain metastases in non-small cell lung cancer","volume":"13","author":"Jablonska PA","year":"2021","unstructured":"Jablonska PA, Bosch-Barrera J, Serrano D,  Challenges and novel opportunities of radiation therapy for brain metastases in non-small cell lung cancer. Cancers (Basel) 2021;13:2141."},{"key":"B73","series-title":"Mol Clin Oncol","first-page":"560","article-title":"Comparison between stereotactic radiosurgery and whole-brain radiotherapy for 10-20 brain metastases from non-small cell lung cancer","volume":"10","author":"Mizuno T","year":"2019","unstructured":"Mizuno T, Takada K, Hasegawa T,  Comparison between stereotactic radiosurgery and whole-brain radiotherapy for 10-20 brain metastases from non-small cell lung cancer. Mol Clin Oncol 2019;10:560\u2013566."},{"key":"B74","series-title":"J Clin Oncol","first-page":"492","article-title":"Treatment for brain metastases: ASCO-SNO-ASTRO guideline","volume":"40","author":"Vogelbaum MA","year":"2022","unstructured":"Vogelbaum MA, Brown PD, Messersmith H,  Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol 2022;40:492\u2013516."},{"key":"B75","series-title":"Cancer J","first-page":"507","article-title":"Predictive biomarkers for immune checkpoint inhibitors in advanced non-small cell lung cancer: current status and future directions","volume":"26","author":"Bhalla S","year":"2020","unstructured":"Bhalla S, Doroshow DB, Hirsch FR. Predictive biomarkers for immune checkpoint inhibitors in advanced non-small cell lung cancer: current status and future directions. Cancer J 2020;26:507\u2013516."},{"key":"B76","series-title":"Clin Cancer Res","first-page":"7412","article-title":"Comparative transcriptome profiling reveals coding and noncoding RNA differences in NSCLC from African Americans and European Americans","volume":"23","author":"Mitchell KA","year":"2017","unstructured":"Mitchell KA, Zingone A, Toulabi L,  Comparative transcriptome profiling reveals coding and noncoding RNA differences in NSCLC from African Americans and European Americans. Clin Cancer Res 2017;23:7412\u20137425."},{"key":"B77","series-title":"Oncotarget","first-page":"5817","article-title":"Fewer actionable mutations but higher tumor mutational burden characterizes NSCLC in Black patients at an urban academic medical center","volume":"10","author":"Choudhury NJ","year":"2019","unstructured":"Choudhury NJ, Eghtesad M, Kadri S,  Fewer actionable mutations but higher tumor mutational burden characterizes NSCLC in Black patients at an urban academic medical center. Oncotarget 2019;10:5817\u20135823."},{"key":"B78","series-title":"J Thorac Oncol","article-title":"PD-L1 expression analysis in African American (AA) and Hispanic lung cancer patients at a minority-based academic cancer center","volume":"12","author":"Shum E","year":"2017","unstructured":"Shum E, Su C, Zhu C,  PD-L1 expression analysis in African American (AA) and Hispanic lung cancer patients at a minority-based academic cancer center. J Thorac Oncol 2017;12(Suppl 2):Abstract P1.07-027."},{"key":"B79","series-title":"JAMA Oncol","first-page":"1952","article-title":"Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer","volume":"6","author":"Shankar B","year":"2020","unstructured":"Shankar B, Zhang J, Naqash AR,  Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer. JAMA Oncol 2020;6:1952\u20131956."},{"key":"B80","series-title":"Lung Cancer","first-page":"71","article-title":"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab","volume":"115","author":"Sato K","year":"2018","unstructured":"Sato K, Akamatsu H, Murakami E,  Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 2018;115:71\u201374."},{"key":"B81","series-title":"J Thorac Dis","first-page":"2706","article-title":"Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer","volume":"12","author":"Sung M","year":"2020","unstructured":"Sung M, Zer A, Walia P,  Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. J Thorac Dis 2020;12:2706\u20132712."},{"key":"B82","series-title":"JAMA Oncol","first-page":"374","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani K","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y,  Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 2018;4:374\u2013378."},{"key":"B83","series-title":"Immunotherapy","first-page":"257","article-title":"Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis","volume":"13","author":"Dall\u2019Olio FG","year":"2021","unstructured":"Dall\u2019Olio FG, Rizzo A, Mollica V,  Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis. Immunotherapy 2021;13:257\u2013270."},{"key":"B84","series-title":"Front Public Health","first-page":"684558","article-title":"Examination of the association between access to care and lung cancer screening among high-risk smokers","volume":"9","author":"Li CC","year":"2021","unstructured":"Li CC, Matthews AK, Kao YH,  Examination of the association between access to care and lung cancer screening among high-risk smokers. Front Public Health 2021;9:684558."},{"key":"B85","series-title":"J Am Coll Radiol","first-page":"122","article-title":"The impact of social determinants of health on lung cancer screening utilization","volume":"19","author":"Shin D","year":"2022","unstructured":"Shin D, Fishman MDC, Ngo M,  The impact of social determinants of health on lung cancer screening utilization. J Am Coll Radiol 2022;19:122\u2013130."},{"key":"B86","series-title":"Cancer Med","first-page":"5362","article-title":"Ethnicity and insurance status predict metastatic disease presentation in prostate, breast, and non-small cell lung cancer","volume":"9","author":"Aghdam N","year":"2020","unstructured":"Aghdam N, McGunigal M, Wang H,  Ethnicity and insurance status predict metastatic disease presentation in prostate, breast, and non-small cell lung cancer. Cancer Med 2020;9:5362\u20135380."},{"key":"B87","series-title":"Cancer","first-page":"3099","article-title":"Association of area-level socioeconomic status and non-small cell lung cancer stage by race\/ethnicity and health care-level factors: analysis of the National Cancer Database","volume":"128","author":"Gupta A","year":"2022","unstructured":"Gupta A, Omeogu CH, Islam JY,  Association of area-level socioeconomic status and non-small cell lung cancer stage by race\/ethnicity and health care-level factors: analysis of the National Cancer Database. Cancer 2022;128:3099\u20133108."},{"key":"B88","series-title":"Ann Thorac Surg","first-page":"1512","article-title":"Disparities in guideline-concordant treatment for pathologic N1 non-small cell lung cancer","volume":"109","author":"Toubat O","year":"2020","unstructured":"Toubat O, Atay SM, Kim AW,  Disparities in guideline-concordant treatment for pathologic N1 non-small cell lung cancer. Ann Thorac Surg 2020;109:1512\u20131520."},{"key":"B89","series-title":"JTO Clin Res Rep","first-page":"100003","article-title":"Veterans Affairs insurance disparities for metastatic lung cancer in the Hawaiian Islands","volume":"1","author":"Lin JQ","year":"2020","unstructured":"Lin JQ, Li SQ, Pezzi TA,  Veterans Affairs insurance disparities for metastatic lung cancer in the Hawaiian Islands. JTO Clin Res Rep 2020;1:100003."},{"key":"B90","series-title":"J Manag Care Spec Pharm","first-page":"1230","article-title":"Coverage of novel therapeutic agents by Medicare prescription drug plans following FDA approval","volume":"24","author":"Shaw DL","year":"2018","unstructured":"Shaw DL, Dhruva SS, Ross JS. Coverage of novel therapeutic agents by Medicare prescription drug plans following FDA approval. J Manag Care Spec Pharm 2018;24:1230\u20131238."},{"key":"B91","series-title":"Medicine (Baltimore)","first-page":"e12715","article-title":"Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016: a cross-sectional study","volume":"97","author":"Roginiel AC","year":"2018","unstructured":"Roginiel AC, Dhruva SS, Ross JS. Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016: a cross-sectional study. Medicine (Baltimore) 2018;97:e12715."},{"key":"B92","series-title":"Oncoimmunology","first-page":"2017162","article-title":"Association between immune-related adverse event timing and treatment outcomes","volume":"11","author":"Hsiehchen D","year":"2022","unstructured":"Hsiehchen D, Naqash AR, Espinoza M,  Association between immune-related adverse event timing and treatment outcomes. Oncoimmunology 2022;11:2017162."},{"key":"B93","series-title":"Med Oncol","first-page":"117","article-title":"Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer","volume":"35","author":"Gibson AJW","year":"2018","unstructured":"Gibson AJW, Li H, D\u2019Silva A,  Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer. Med Oncol 2018;35:117."},{"key":"B94","series-title":"Radiother Oncol","first-page":"104","article-title":"Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data","volume":"130","author":"Lehrer EJ","year":"2019","unstructured":"Lehrer EJ, Peterson J, Brown PD,  Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data. Radiother Oncol 2019;130:104\u2013112."},{"key":"B95","series-title":"Neuro Oncol","first-page":"1060","article-title":"The impact of sequencing PD-1\/ PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis","volume":"21","author":"Kotecha R","year":"2019","unstructured":"Kotecha R, Kim JM, Miller JA,  The impact of sequencing PD-1\/ PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis. Neuro Oncol 2019;21:1060\u20131068."},{"key":"B96","series-title":"Int J Radiat Oncol Biol Phys","first-page":"624","article-title":"Improved overall survival and locoregional disease control with concurrent PD-1 pathway inhibitors and stereotactic radiosurgery for lung cancer patients with brain metastases","volume":"101","author":"Schapira E","year":"2018","unstructured":"Schapira E, Hubbeling H, Yeap BY,  Improved overall survival and locoregional disease control with concurrent PD-1 pathway inhibitors and stereotactic radiosurgery for lung cancer patients with brain metastases. Int J Radiat Oncol Biol Phys 2018;101:624\u2013629."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/12\/article-p1269.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/21\/12\/article-p1269.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/21\/12\/article-p1269.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T20:51:28Z","timestamp":1702327888000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/12\/article-p1269.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":96,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2023.7064","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}